| Firmonertinib studied in …STUDIED_INderived52 of 52show fewer |
|---|
| → studied in | NCT07622186Phase 2 · recruiting A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07185997Phase 3 · recruiting Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05987826Phase 2 · recruiting Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04858958Phase 1 · completed Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05466149Phase 2 · active not recruiting Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06812871Phase 2 · completed High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis · 52 trials list this drug (34 active) | — | — | Meningeal Carcinomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04853342Phase 3 · recruiting To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06956001Phase 3 · recruiting Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06970639Phase 3 · recruiting A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases · 52 trials list this drug (34 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07482605Phase 2 · not yet recruiting Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion · 52 trials list this drug (34 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07314216Phase 2 · recruiting Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07661173Phase 2 · not yet recruiting A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07655622Phase 1/Phase 2 · recruiting Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07517640Phase 2 · not yet recruiting Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868732Phase 1 · recruiting Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05364073Phase 1 · active not recruiting Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365410Phase 2 · not yet recruiting Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study · 52 trials list this drug (34 active) | — | — | Brain Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07298148Phase 2 · not yet recruiting Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07304739Phase 2 · recruiting Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06652048Phase 2 · recruiting High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07239102completed Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis · 52 trials list this drug (34 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07229599Phase 1/Phase 2 · recruiting A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer · 52 trials list this drug (34 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07193160Phase 2 · not yet recruiting Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07182708Phase 2 · not yet recruiting High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07092202Phase 4 · recruiting Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma,Meningeal Carcinomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05607550Phase 3 · active not recruiting Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05994131Phase 1/Phase 2 · recruiting IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02973763Phase 1 · terminated Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03127449NA · terminated AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03452592Phase 2 · terminated Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M · 52 trials list this drug (34 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04958967Phase 1 · withdrawn Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06643000NA · recruiting Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma,Meningeal Carcinomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06674343Phase 3 · recruiting Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05379803Phase 2 · recruiting High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06394674Phase 2 · recruiting High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06483672Phase 2 · not yet recruiting Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases · 52 trials list this drug (34 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06352502unknown An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis · 52 trials list this drug (34 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06339242Phase 2 · unknown A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06319950Phase 2 · not yet recruiting High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases · 52 trials list this drug (34 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06192849Phase 2 · recruiting To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06117644not yet recruiting The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05813522Phase 2 · unknown Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05445310Phase 2 · unknown Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04895930Phase 2 · unknown Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05334277Phase 2 · recruiting Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05503667Phase 2 · recruiting Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma · 52 trials list this drug (34 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05255406Phase 2 · unknown Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05165355Phase 2 · unknown Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05079022Phase 1/Phase 2 · unknown ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas · 52 trials list this drug (34 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04982900Phase 2 · unknown Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities · 52 trials list this drug (34 active) | — | — | Malignant Neoplasm of Lung - Multiple Primary Sites | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04970693Phase 2 · unknown A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression · 52 trials list this drug (34 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04965831Phase 2 · unknown Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) · 52 trials list this drug (34 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |